In the present study, we demonstrate that CRISPR/Cas13-mediated knockdown of Frmd4a, a factor associated with brain developmental disorders and a known risk factor for Alzheimer’s disease, or its homolog Frmd4b, results in decreased process elongation and decreased neuronal marker expression in cells. This evidence concerns the gene FRMD4B and Alzheimer disease.